Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label Study To Assess the Safety and Tolerability of AT2101 in Treatment-naive Adult Patients With Type 1 Gaucher Disease

NCT00446550 is registered in ClinicalTrials.gov with Amicus Therapeutics as lead sponsor.

NCT NCT00446550
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00446550 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label Study To Assess the Safety and Tolerability of AT2101 in Treatment-naive Adult Patients With Type 1 Gaucher Disease
Lead sponsor
Amicus Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
June 11, 2008
Completion date
August 20, 2009
Enrollment
19 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

gaucher disease, gaucher disease, type 1, type 1 gaucher disease